Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 3/20 | 0.60 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.60 |
| ▸ | GPR27 | Q9NS67 | 11/20 | 0.59 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | F2R | P25116 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30926774 | 1.00 | KCNK3 (0.60) | KCNK3KCNK9GPR27AVPR2CYP19A1 | |
| SCHEMBL5119995 | 0.81 | RXFP1 (0.70) | GPR27AVPR2RXFP1 | |
| SCHEMBL27179849 | 0.80 | KMT2A (0.70) | KCNK3KCNK9GPR27AVPR2CYP19A1 | |
| SCHEMBL30926705 | 0.80 | KMT2A (0.70) | KCNK3KCNK9GPR27AVPR2CYP19A1 | |
| SCHEMBL27181433 | 0.80 | CYP19A1 (0.60) | GPR27AVPR2CYP19A1 | |
| SCHEMBL30926996 | 0.80 | CYP19A1 (0.60) | GPR27AVPR2CYP19A1 | |
| SCHEMBL30927072 | 0.79 | GPR27 (0.71) | GPR27AVPR2CYP19A1 | |
| SCHEMBL27181559 | 0.79 | GPR27 (0.71) | GPR27AVPR2CYP19A1 | |
| SCHEMBL14372379 | 0.76 | PTGS1 (0.68) | KCNK3KCNK9PTGS1F2RRXFP1 | |
| SCHEMBL5115424 | 0.76 | SLC20A2 (0.66) | GPR27AVPR2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580404-A2 | SULFONAMIDE APYRASE INHIBITORS | Texas Crop Science, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. | 2024-03-28 | — | — | US | claimed |
| WO-2024050041-A2 | SULFONAMIDE APYRASE INHIBITORS | TEXAS CROP SCIENCE (US) | 2024-03-07 | — | — | WO | claimed |
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | APEH, ARSA, DNPEP | KCNK3 3991/4885KCNK9 3433/4885GPR27 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.